Walgreens Boots Alliance Reports Q2 Beat, But Guidance Implies Significant Deceleration in H2/22
<p><a href='https://financialmodelingprep.com/financial-summary/WBA'>Walgreens Boots (NASDAQ:WBA) </a>shares lost around 7% since the company’s reported Q2 results two days ago. While the company beat the Street expectations, the guidance of low-single-digit EPS growth was reiterated, implying a significant deceleration in H2/22 due to labor and Walgreens Health investments.</p>
<p>Q2 adjusted EPS came in at $1.59, compared to the estimates of $1.37, and revenue at $33.76 billion, compared to the consensus of $33.32 billion. The company benefited from strong vaccination and testing demand, solid US retail demand, and continued improvement in international markets. </p>
<p>Analysts at RBC Capital reiterated their Sector Perform rating but lowered their price target to $46 from $52 as they roll their valuation forward to 2023 to reflect a more normalized post-pandemic operating backdrop.</p>

NASDAQ:WBA